499 related articles for article (PubMed ID: 25934077)
21. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
[TBL] [Abstract][Full Text] [Related]
22. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Tan CS; Gilligan D; Pacey S
Lancet Oncol; 2015 Sep; 16(9):e447-e459. PubMed ID: 26370354
[TBL] [Abstract][Full Text] [Related]
23. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
Galvani E; Sun J; Leon LG; Sciarrillo R; Narayan RS; Sjin RT; Lee K; Ohashi K; Heideman DA; Alfieri RR; Heynen GJ; Bernards R; Smit EF; Pao W; Peters GJ; Giovannetti E
Oncotarget; 2015 Dec; 6(40):42717-32. PubMed ID: 26015408
[TBL] [Abstract][Full Text] [Related]
24. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
[TBL] [Abstract][Full Text] [Related]
25. [3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].
Brosseau S; Viala M; Varga A; Planchard D; Besse B; Soria JC
Bull Cancer; 2015 Sep; 102(9):749-57. PubMed ID: 26235419
[TBL] [Abstract][Full Text] [Related]
26. Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors.
Lowder MA; Doerner AE; Schepartz A
J Am Chem Soc; 2015 May; 137(20):6456-9. PubMed ID: 25973741
[TBL] [Abstract][Full Text] [Related]
27. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
[TBL] [Abstract][Full Text] [Related]
28. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paik PK; Drilon A; Fan PD; Yu H; Rekhtman N; Ginsberg MS; Borsu L; Schultz N; Berger MF; Rudin CM; Ladanyi M
Cancer Discov; 2015 Aug; 5(8):842-9. PubMed ID: 25971939
[TBL] [Abstract][Full Text] [Related]
29. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.
Frenel JS; Carreira S; Goodall J; Roda D; Perez-Lopez R; Tunariu N; Riisnaes R; Miranda S; Figueiredo I; Nava-Rodrigues D; Smith A; Leux C; Garcia-Murillas I; Ferraldeschi R; Lorente D; Mateo J; Ong M; Yap TA; Banerji U; Gasi Tandefelt D; Turner N; Attard G; de Bono JS
Clin Cancer Res; 2015 Oct; 21(20):4586-96. PubMed ID: 26085511
[TBL] [Abstract][Full Text] [Related]
30. Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.
Engelman JA; Oser MG; Niederst MJ; Sequist LV
Lancet Oncol; 2015 Jul; 16(7):e309-10. PubMed ID: 26149875
[No Abstract] [Full Text] [Related]
31. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
[TBL] [Abstract][Full Text] [Related]
32. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.
Scheffler M; Merkelbach-Bruse S; Bos M; Fassunke J; Gardizi M; Michels S; Groneck L; Schultheis AM; Malchers F; Leenders F; Kobe C; König K; Heukamp LC; Sos ML; Thomas RK; Büttner R; Wolf J
J Thorac Oncol; 2015 Jun; 10(6):e40-3. PubMed ID: 26001148
[No Abstract] [Full Text] [Related]
33. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
34. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
Tartarone A; Lerose R
Ther Adv Respir Dis; 2015 Oct; 9(5):242-50. PubMed ID: 26016841
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Uchida J; Imamura F; Kukita Y; Oba S; Kumagai T; Nishino K; Inoue T; Kimura M; Kato K
Cancer Sci; 2016 Mar; 107(3):353-8. PubMed ID: 26678713
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
37. [TKI Resistance for T790M Mutation].
Wang H; Guo R; Zhang L
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):245-50. PubMed ID: 25936890
[TBL] [Abstract][Full Text] [Related]
38. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.
Piotrowska Z; Sequist LV
Cancer J; 2015; 21(5):371-7. PubMed ID: 26389761
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
